Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| JAK2 | 60-95% | JAK2 V617F by subtype | doi.org |
| G-CSF receptor (CSF3R) Two mutation regions with different kinase dependencies (SRC family or JAK); ruxolitinib response reported in a JAK-type case | 59% | Activating CSF3R mutation in chronic neutrophilic leukaemia or atypical BCR-ABL1-negative CML, 16 of 27 patients | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.